

ISPOR 30th HTA-P&T Roundtable [North America]

Sunday, May 22th -- 12:00 PM - 6:00 PM Washington Hilton Hotel Washington, DC, USA

Participants

<u>United States</u> Suzanne Belinson PhD, MPH Executive Director, Center for Clinical Effectiveness Blue Cross Blue Shield Association Chicago, IL, USA

Elise Berliner, PhD Director, Technology Assessment Program Agency for Healthcare Research and Quality (AHRQ) Rockville, MD, USA

Jessica Daw, PharmD, MBA Director of Pharmacy UPMC Health Plan Pittsburgh, PA, USA

Patrick Gleason, PharmD, BCPS, FCCP Director, Health Outcomes Prime Therapeutics Minneapolis, MN, USA

Rochelle Henderson, PhD Sr. Director Research and Analytics Express Scripts, Inc. St. Louis, MO, USA

Sean Karbowicz, PharmD Director, Policy and Clinical Business Development OmedaRx Portland, OR, USA

Andrea Marks, MS Chief Analytics Officer OptumRx Chicago, IL, USA

Josh Morse, MPH Program Director, Washington State Health Technology Assessment Program Washington State Health Care Authority Olympia, WA, USA Steven D. Pearson, MD, MSc President Institute for Clinical and Economic Review Boston, MA USA

Chuck Shih, PhD Senior Officer, Specialty Drugs The Pew Charitable Trusts Washington, DC, USA

Donna Sullivan, PharmD, MS Chief Pharmacy Officer, Washington State Prescription Drug Program **Washington State Health Care Authority** Olympia, WA, USA

John Watkins, PharmD, MPH, BCPS Pharmacy Manager, Formulary Development Premera Blue Cross Mountlake Terrace, WA, USA

Jeff T. White, PharmD, MS Director, Drug Evaluation and Clinical Analytics Anthem Newport Coast, CA, USA

Karen Worley, PhD Research Leader, Comprehensive Health Insights Humana, Inc. Cincinnati, OH, USA

Canada Brent Fraser, MBA, BSc Vice-President, Pharmaceutical Reviews Canadian Agency for Drugs and Technologies in Health (CADTH) Toronto, ON, Canada

Judy McPhee, BScPharm Executive Director, Pharmaceutical Services Department of Health and Wellness, Government of Nova Scotia Halifax, NS, Canada

Brian O'Rourke, PharmD President and Chief Executive Director, **Canadian Agency for Drugs and Technologies in Health (CADTH)** Chair, **The International Network of Agencies for Health Technology Assessment (INAHTA)** Ottawa, ON, Canada

Denis A. Roy, MD, MPH, MSc, FRCPC Vice-President, Science and Clinical Governance **National Institute for Excellence in Health and Social Science (INESSS)** Québec, QC, Canada

Kevin Wilson Executive Director, Drug Plan and Extended Benefits Branch Saskatchewan Ministry of Health Regina, SK, Canada Europe **Professor Finn Børlum Kristensen, MD, PhD** Chairman of the Executive Committee, **EUnetHTA** Coordinating Secretariat Director, **Danish Health and Medicines Authority** Adjunct Professor, Health Services Research & HTA, **University of Southern Denmark** Copenhagen, Denmark

Mirjana Huić, MD, PhD

Clinical Pharmacologist and Toxicologist Assistant Director, Department for Development, Research and Health Technology Assessment **Agency for Quality and Accreditation in Health Care and Social Welfare** Zagreb, Croatia

Rabia Kahveci, MD, MScHTA Professor, Ankara Numune Hospital Chair, ANHTA (Ankara Numune HTA Unit) Consultant, HTA Unit, Ministry of Health (Agency for Pharmaceuticals and Medical Devices) Director, HTAi Ankara, Turkey

Invited Speaker Brian Solow, MD, FAAFP Chief Medical Officer Optum Life Sciences Irvine, CA, USA

ISPOR Staff

Nancy Berg, CEO & Executive Director, ISPOR, Lawrenceville, NJ, USA Nadia Naaman, Senior Director, Scientific & Health Policy Initiatives, ISPOR, Lawrenceville, NJ, USA Julia Chamova, MBA, Director, Global Networks - Europe, Middle East, and Africa (EMEA), ISPOR, Malmö, Sweden

Kelly Lenahan, Assistant Manager, Scientific & Health Policy Initiatives, ISPOR, Lawrenceville, NJ, USA